#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hodgkin's disease refractory Ductal adenocarcinoma of pancreas Multiple system atrophy Ependymoma Infertility female Endometrial cancer Polycystic liver disease Breast cancer Congenital leptin deficiency Endometrial cancer recurrent Pemphigus Peritoneal mesothelioma malignant Chondrosarcoma metastatic Sarcoma Neutropenia More trials…

    Learn about Rare Diseases

    Rett syndrome – Trials in Disease Lymphatic malformation – Diagnostics Pleomorphic leiomyosarcoma Waldenstrom’s macroglobulinaemia refractory – Treatment Bronchopulmonary dysplasia Marfan’s syndrome – Trials in Disease Sjogren’s syndrome Cerebral arteriovenous malformation haemorrhagic Angiosarcoma – Treatment Hyperoxaluria – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ravulizumab Lebrikizumab Cefiderocol Keto-Leucine Calcium Oric-114 Lerodalcibep Gsk3858279 Dyp688 Avalotcagene Ontaparvovec Mavorixafor Carfilzomib Levoleucovorin Disodium Clindamycin NERANDOMILAST PEGZILARGINASE Fluorodopa (18F) ACETYLCARNITINE HYDROCHLORIDE Celecoxib Piflufolastat (18F) Clenbuterol Hydrochloride More therapies…

    Learn about Your Condition

    Endocarditis enterococcal Abdominal wall pain Subarachnoid haemorrhage Iron deficiency Premature rupture of membranes Viral infection Ischaemic stroke Dermatomyositis Haemorrhage intracranial Colon cancer metastatic Adenosquamous cell lung cancer Post cardiac arrest syndrome Cerebral amyloid angiopathy Aicardi-Goutieres syndrome Cataract More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Follicle centre lymphoma follicular grade I, II – III

  • A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Odronextamab
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Austria Belgium Czechia France Germany Italy +2

  • Study of Long-term Safety of Tazemetostat in Patients Who Previously Participated in Tazemetostat Clinical Trials

    Not recruiting

    1 1 1
    Investigated Drugs:
    • Tazemetostat
    France Poland

  • Study on the Effects and Safety of Odronextamab for Adults with Previously Treated B-cell Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Non-Hodgkin’s lymphoma unspecified histology aggressive
    • Marginal zone lymphoma
    • B-cell lymphoma
    Investigated Drugs:
    • Odronextamab
    France Germany Italy Poland Spain

  • Study of Mosunetuzumab for Patients with Early Relapse of Follicular Lymphoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Follicular lymphoma
    Investigated Drugs:
    • Mosunetuzumab
    Denmark Finland Norway Sweden

  • Study Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Marginal zone lymphoma
    Investigated Drugs:
    • Zanubrutinib
    • Lenalidomide
    • Obinutuzumab
    Austria Belgium Bulgaria Czechia France Germany +8

  • Study Comparing Tisagenlecleucel with Standard Treatment for Adults with Relapsed or Refractory Follicular Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Tisagenlecleucel
    • Cyclophosphamide Monohydrate
    • Fludarabine Phosphate
    Austria Czechia Hungary Poland Romania Slovakia +1

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!